Morich Frank Form 3 Isoray / Frank Morich ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Morich Frank

(Last) (First) (Middle)

350 HILLS ST, STE 106

(Street)

RICHLAND WA 99354

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/03/2023

3. Issuer Name and Ticker or Trading Symbol
Isoray, Inc. [ ISR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(1)	02/28/2031	Common Stock	632,840	(2)	D
Stock Options (right to buy)	(1)	05/18/2032	Common Stock	474,631	(3)	D

Explanation of Responses:

1. Fully vested as of 2/3/2023 due to acceleration as a result of merger of Viewpoint Molecular Targeting, Inc. into wholly owned subsidiary of Isoray, Inc. (the "Merger").

2. Received in exchange for options to acquire 200,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.27 per share pursuant to the terms of the Merger.

3. Received in exchange for options to acquire 150,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.13 per share pursuant to the terms of the Merger.

	/s/ Frank Morich	02/13/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.